Eritoran; resatorvid | Toll-like receptor 4 antagonist; Eritoran is structurally similar to lipopolysaccharide – A of Gram-negative bacteria. Resatorvid is a direct antagonist of toll like receptor 4 | Anti-inflammatory; Immunomodulation |
Polymixin B fibre column; CytoSorb | Hemoperfusion; CytoSorb has hemadsorption properties | Removal of circulating endotoxin and bacterial components |
Plasma exchange; Whole blood exchange; Coupled plasma filtration adsorption; Hemofiltration | Exchange of plasma or blood with or without sorbent adsorption; either continuous or intermittent; low or high volume | Removal of endotoxins and circulating cytokines |
Macrolides | Nuclear factor kB and AP-1 signalling suppression, inhibition of ERK-1 and 2 pathways | Anti-inflammatory and immunomodulating properties |
Interferon-gamma | Increase in monocyte HLA-DR expression | Restores immune regulation, abolishes immunoparalysis by restoring monocyte function |
Immunoglobulins | Increase in IgA and IgM levels | Boosts humoral immunity |
Granulocyte macrophage colony stimulating factor | Promotes maturation and differentiation of neutrophils, monocytes, macrophages, dendritic cells, T lymphocytes and plasma cells | Improves immune regulation, reduces immunoparalysis |
Anti-MIF | Antagonizes macrophage migration inhibition factor | Immunomodulation through boosting activity of endogenous glucocorticoids |
Super-Antigen-Antagonist | Suppression of pro-inflammatory gene expression by inhibition of T cell activation | Th1 blockade and prevention of lethal shock |
Heparin and its analogues | Anti-thrombotic, immunomodulation | Prevents early disseminated intravascular coagulation, prevents early organ failures due to diffuse system microvascular thrombosis |
Naloxone | Opioid receptor antagonism | Improves hemodynamic instability |
Pentoxifylline | Decreases erythrocyte aggregation and deformability, anti TNF-alpha effect | Improvement in arterial oxygen tension by improving fractionated oxygen exchange |
GTS-21 | Selective alpha-7-nicotinic acetylcholine receptor agonist, blocks nuclear factor – kB and cytokines downstream | Activates cholinergic anti-inflammatory pathway |
Interleukin 7 and 2 | Pro-inflammatory cytokines | Prevents immunoparalysis |
Programmed cell death-1 (PD-1) and ligand (PD-L1) antagonist | Prevention of lymphocyte depletion, improvement in pro-inflammatory mediators and increased bacterial clearance | Immune modulation |
B and T cell lymphocyte attenuator antagonism (BTLA) | Increases activity and proliferation of T cells | Increases resistance to endotoxin and prevention of endotoxin mediated shock |
Antagonism of cytotoxic T lymphocyte antigen 4 (CTLA-4) | Increased activity and proliferation of T cells | Abolishes endotoxemia and associated toxic shock |
Methylthiouracil | Suppresses high mobility group box – 1 (HMGB-1) | Anti-inflammatory |
Structurally nanoengineered antimicrobial peptide polymers; Ceria – zirconia nanoparticles; Piceatannol-loaded albumin nanoparticles; Sialic-acid decorated nanoparticles; Exsosomes loaded with MFGE8, miR-223; Red blood cells and macrophage coated nanoparticles; Liposomes tagged to antimicrobials; Opsonin bound magnetic nanobeads | Nanoparticle technology (pre-clinical studies) | Antibacterial; Antioxidant; Anti-inflammatory; Endotoxin antagonist; Extracorporeal blood cleansing; Clearance of apoptotic cells |